

CITATION REPORT

List of articles citing

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

DOI: 10.1056/nejmoa1509981

New England Journal of Medicine, 2016, 374, 323-32.

Source: <https://exaly.com/paper-pdf/65409212/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
734	BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia. 2016 , 8, e2016011		16
733	Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy. 2016 , 7, 317		24
732	Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?. 2016 , 35, e387-98		17
731	A rare case of the upper extremity diffuse large B-cell lymphoma mimicking soft tissue sarcoma in an elderly patient. 2016 , 3, 25		2
730	Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy. 2016 , 22, 6484-500		58
729	Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. 2016 , 11, e0159607		39
728	Recent advances in therapy of chronic lymphocytic leukaemia. 2016 , 174, 351-67		17
727	Targeting B-cell receptor signaling in leukemia and lymphoma: how and why?. 2016 , 5, 37-53		4
726	Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children. 2016 , 173, 531-44		10
725	Advances in the treatment of chronic lymphocytic leukaemia. 2016 , 147, 447-454		
724	Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. 2016 , 128, 2199-2205		135
723	Novel agents in chronic lymphocytic leukemia. 2016 , 2016, 137-145		13
722	First-line therapy for young patients with CLL. 2016 , 2016, 146-148		0
721	Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group. 2016 , 101, 1573-1580		88
720	Enhanced Expression of Bruton's Tyrosine Kinase in B Cells Drives Systemic Autoimmunity by Disrupting T Cell Homeostasis. 2016 , 197, 58-67		33
719	Transplantation in CLL: what we can learn from a dinosaur. 2016 , 51, 765-6		
718	Novel therapies under investigation for mantle cell lymphoma. 2016 , 25, 375-80		2

717	Mechanisms of tumor cell resistance to the current targeted-therapy agents. 2016 , 37, 10021-39	50
716	Structure-based discovery of novel 4,5,6-trisubstituted pyrimidines as potent covalent Bruton's tyrosine kinase inhibitors. 2016 , 26, 3052-3059	9
715	Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets. 2016 , 57, 1991-2013	17
714	Second-generation inhibitors of Bruton tyrosine kinase. 2016 , 9, 80	122
713	Speed bumps on the road to a chemotherapy-free world for lymphoma patients. 2016 , 128, 325-30	16
712	[Advances in the treatment of chronic lymphocytic leukaemia]. 2016 , 147, 447-454	
711	Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej białaczki limfocytowej w 2016 r. Raport Grupy Roboczej PTHi i PALG-CLL. 2016 , 47, 169-183	1
710	Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. 2016 , 12, 1381-1392	23
709	Prospect & progress of venetoclax in treating chronic lymphocytic leukemia. 2016 , 4, 1087-1093	
708	Future therapeutic options for patients with Waldenström macroglobulinemia. 2016 , 29, 206-215	4
707	NF- κ B activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions. 2016 , 39, 40-8	38
706	Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. 2016 , 101, e295-8	54
705	Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations. 2016 , 11, 2897-2907	82
704	New drugs for follicular lymphoma. 2016 , 49, 38-46	3
703	Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?. 2016 , 16 Suppl, S74-81	17
702	Promising Novel Agents for Aggressive B-Cell Lymphoma. 2016 , 30, 1229-1237	5
701	Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system. 2016 , 7, 10934	45
700	Autoimmune hemolytic anemia (AIHA) associated with chronic lymphocytic leukemia in the current era of targeted therapy. 2016 , 50, 31-36	15

699	Novel therapeutic targets in Waldenstrom macroglobulinemia. 2016 , 29, 216-228	7
698	Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. 2016 , 7, 179-86	22
697	Targeted Therapy of CLL. 2016 , 39, 768-778	5
696	Management of elderly and unfit patients with chronic lymphocytic leukemia. 2016 , 9, 1165-1175	4
695	The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia. 2016 , 9, 1177-1187	2
694	Utility of preclinical assays to assess stored platelet function. 2016 , 23, 563-567	1
693	New Agents to Treat Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016 , 374, 2186-2192	6
692	Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?. 2016 , 9, 679-93	2
691	A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy. 2016 , 95, 1137-43	24
690	Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. 2016 , 9, 21	140
689	HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis. 2016 , 18, 91	46
688	Targeting tumor tolerance: A new hope for pancreatic cancer therapy?. 2016 , 166, 9-29	22
687	Synchronous biphenotypic Richter syndrome with Epstein-Barr virus-positive nodal classical Hodgkin lymphoma and bone marrow diffuse large B-cell lymphoma. 2016 , 69, 707-10	2
686	Progress in Chronic Lymphocytic Leukemia with Targeted Therapy. <i>New England Journal of Medicine</i> , 2016 , 374, 386-8	59.2 5
685	Breakthrough therapies in B-cell non-Hodgkin lymphoma. 2016 , 27, 778-87	31
684	Chronic lymphocytic leukemia therapy: new targeted therapies on the way. 2016 , 17, 1077-89	11
683	Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents. 2016 , 11, 52-60	5
682	Arresting the Inflammatory Drive of Chronic Lymphocytic Leukemia with Ibrutinib. 2016 , 22, 1547-9	9

681	The molecular pathogenesis of chronic lymphocytic leukaemia. 2016 , 16, 145-62	170
680	Haematological cancer: Targeted agents: efficacy RESONATEs better with fine tuning. 2016 , 13, 63	
679	Inhibition of MicroRNA miR-222 with LNA Inhibitor Can Reduce Cell Proliferation in B Chronic Lymphoblastic Leukemia. 2017 , 33, 327-332	6
678	Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant. 2017 , 31, 177-185	32
677	Chronic lymphocytic leukaemia. 2017 , 3, 16096	219
676	Pseudokinases: update on their functions and evaluation as new drug targets. 2017 , 9, 245-265	49
675	Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia. 2017 , 23, 4527-4533	43
674	Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. 2017 , 31, 2075-2084	104
673	Front-line treatment of CLL in the era of novel agents. 2017 , 53, 70-78	19
672	Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease. 2017 , 69, 1313-1324	58
671	How I manage patients with hairy cell leukaemia. 2017 , 177, 543-556	24
670	The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. 2017 , 12, 11-19	33
669	Discovery and evaluation of 1H-pyrrolo[2,3-b]pyridine based selective and reversible small molecule BTK inhibitors for the treatment of rheumatoid arthritis. 2017 , 27, 1867-1873	4
668	Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia. 2017 , 148, 381.e1-381.e9	1
667	Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia. 2018 , 249, 203-229	5
666	Distinct and Overlapping Functions of TEC Kinase and BTK in B Cell Receptor Signaling. 2017 , 198, 3058-3068	10
665	Management of atrial fibrillation in patients taking targeted cancer therapies. 2017 , 3, 2	9
664	What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?. 2017 , 18, 12	6

663	Targeted Therapy in Chronic Lymphocytic Leukemia (CLL). 2017 , 12, 20-28	6
662	Targeting indolent non-Hodgkin lymphoma. 2017 , 10, 299-313	3
661	Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. 2017 , 15, 835-847	130
660	Magic pills: new oral drugs to treat chronic lymphocytic leukemia. 2017 , 18, 411-425	6
659	Current Treatment of Chronic Lymphocytic Leukemia. 2017 , 18, 5	14
658	Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia. 2017 , 135, 60-69	22
657	Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development. 2017 , 12, 733-745	2
656	USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status. 2017 , 130, 156-166	41
655	The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia. 2017 , 58, 2287-2297	7
654	Small-Molecule Inhibitors of Bruton's Tyrosine Kinase. 2017 , 75-104	1
653	Treatment of chronic lymphocytic leukemia in older adults. 2017 , 8, 315-319	9
652	Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma. 2017 , 12, 207-216	10
651	An update for Richter syndrome - new directions and developments. 2017 , 178, 508-520	23
650	Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia. 2017 , 18, 857-873	2
649	The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. 2017 , 23, 2831-2841	88
648	Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib. 2017 , 31, 1117-1122	33
647	Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. 2017 , 31, 1333-1339	57
646	Novel approaches to targeting MYD88 in Waldenström macroglobulinemia. 2017 , 10, 739-744	4

645	Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia. 2017 , 148, 381.e1-381.e8	
644	The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia. 2017 , 16, 1079-1088	9
643	Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies. 2017 , 34, 509-527	27
642	Joining Forces: The Chemical Biology-Medicinal Chemistry Continuum. 2017 , 24, 1058-1065	12
641	Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. 2017 , 28, 1050-1056	139
640	Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition. 2017 , 36, 4653-4661	21
639	Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059. 2017 , 129, 2808-2810	39
638	Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia. 2017 , 96, 1185-1196	20
637	Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity. 2017 , 140, 875-879.e1	27
636	PI3K signaling in cancer: beyond AKT. 2017 , 45, 62-71	238
635	Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future. 2017 , 10, 425-432	3
634	Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib. 2017 , 96, 1175-1184	37
633	Targeting of B-cell receptor signalling in B-cell malignancies. 2017 , 282, 415-428	29
632	A Perfect Storm: Tyrosine Kinase Inhibitor-Associated Polymorphic Ventricular Tachycardia. 2017 , 52, e123-e127	8
631	Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). 2017 , 31, 1872-1881	46
630	The landscape of new drugs in lymphoma. 2017 , 14, 335-346	49
629	Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. 2017 , 23, 3734-3743	82
628	Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines. 2017 , 25, 765-772	13

627	Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. 2017 , 13, 11-26	265
626	Rationale for combinatory chronic lymphocytic leukaemia treatment paradigms in the era of the B-cell receptor pathway and anti-apoptotic inhibitors: how do we mix, match, and move forward?. 2017 , 176, 337-340	
625	Bruton's Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in Rats. 2017 , 360, 226-238	13
624	Next Generation Small Molecules. 2017 , 17, S203-S204	
623	MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia. 2017 , 77, 7038-7048	33
622	In Silico Identification of a Novel Hinge-Binding Scaffold for Kinase Inhibitor Discovery. 2017 , 60, 8552-8564	20
621	Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia. 2017 , 26, 1249-1265	27
620	Potential applications of Bruton's tyrosine kinase inhibitors for the prevention of allergic reactions. 2017 , 13, 921-923	10
619	Combination therapy with the type II anti-CD20 antibody obinutuzumab. 2017 , 26, 1145-1162	4
618	Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. 2017 , 363, 240-252	198
617	Differential Kinobeads Profiling for Target Identification of Irreversible Kinase Inhibitors. 2017 , 12, 2515-2521	16
616	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors. 2017 , 27, 1305-1318	6
615	What Is the Role of Chemotherapy in Patients With Chronic Lymphocytic Leukemia?. 2017 , 17, 723-727	4
614	Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies. 2017 , 17, 834-851	32
613	Targeting B Cell Signaling in Chronic Lymphocytic Leukemia. 2017 , 19, 61	13
612	Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. 2017 , 92, 946-965	177
611	New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia. 2017 , 12, 1041-1052	2
610	Combined BTK and PI3K Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model. 2017 , 23, 5814-5823	25

609	The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable activity against chronic lymphocytic leukemia B cells with CD20 antibodies. 2017 , 102, e400-e403	33
608	Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives. 2017 , 26, 909-915	22
607	Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. 2017 , 58, 1376-1383	30
606	Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC). 2017 , 45, 36-49	8
605	Rapid onset of hemophagocytic lymphohistiocytosis in a patient with refractory chronic lymphocytic leukemia treated with ibrutinib. 2017 , 58, 1258-1261	2
604	NF-B signaling pathway and its potential as a target for therapy in lymphoid neoplasms. 2017 , 31, 77-92	54
603	From identification of the BTK kinase to effective management of leukemia. 2017 , 36, 2045-2053	38
602	How to unleash mitochondrial apoptotic blockades to kill cancers?. 2017 , 7, 18-26	37
601	Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines. 2017 , 126, 444-455	24
600	Management of relapsed and refractory mantle cell lymphoma: a review of current evidence and future directions for research. 2017 , 1, 1-1	
599	Safety profiles of novel agent therapies in CLL. 2017 , 2017, 354-357	0
598	How should we sequence and combine novel therapies in CLL?. 2017 , 2017, 346-353	14
597	Ibrutinib. 2017 , 609-637	1
596	Peptide and Protein-Based Therapeutic Agents*. 2017 , 145-167	6
595	Syk inhibitors in clinical development for hematological malignancies. 2017 , 10, 145	79
594	Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia. 2017 , 1, 1867-1875	15
593	Covalent Kinase Inhibitors for Cancer. 2017 , 76-103	
592	Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia. 2017 , 10, 645-656	7

591	Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia. 2017 , 13, 371-377	14
590	Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. 2017 , 1, 2610-2623	71
589	Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. 2018 , 61, 2227-2245	119
588	Frontline Therapy of CLL: Evolving Treatment Paradigm. 2018 , 13, 69-77	11
587	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). 2018 , 24 Suppl 2, S53-S70	93
586	Multidomain Control Over TEC Kinase Activation State Tunes the T Cell Response. 2018 , 36, 549-578	18
585	BTK Inhibitors: Focus on Ibrutinib and Similar Agents. 2018 , 1-22	
584	Electrophysiologic Toxicity of Chemoradiation. 2018 , 20, 45	17
583	Monitoring and Management of Toxicities of Novel B Cell Signaling Agents. 2018 , 20, 49	14
582	Lymphoid Leukemias in Adults. 2018 , 422-433	1
581	Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma. 2018 , 65, 41-46	20
580	Encyclopedia of Signaling Molecules. 2018 , 522-522	
579	Targeting B cell receptor signalling in cancer: preclinical and clinical advances. 2018 , 18, 148-167	159
578	Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects. 2018 , 181, 306-319	47
577	Ibrutinib and its use in the treatment of chronic lymphocytic leukemia. 2018 , 14, 681-697	
576	and evidence for uncoupling of B-cell receptor internalization and signaling in chronic lymphocytic leukemia. 2018 , 103, 497-505	6
575	How I treat CLL patients with ibrutinib. 2018 , 131, 379-386	74
574	Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3K in Mature B-cell Malignancies. 2018 , 24, 1103-1113	10

573	Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia. 2018 , 9, 3-19	16
572	Chimeric antigen receptor-modified T cells: CD19 and the road beyond. 2018 , 131, 2621-2629	96
571	Role of Bruton's tyrosine kinase in B cells and malignancies. 2018 , 17, 57	225
570	Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms. 2018 , 189, 89-103	62
569	Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors. 2018 , 61, 4608-4627	10
568	Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections. 2018 , 32, 387-399	34
567	Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans. 2018 , 131, 2605-2616	52
566	Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2018 , 378, 1107-1120	59.2 455
565	The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review. 2018 , 151, 315-326	84
564	Treatment of Chronic Lymphocytic Leukemia and Related Disorders. 2018 , 117-134	
563	Design, synthesis and biological evaluation of novel 3-substituted pyrazolopyrimidine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors. 2018 , 26, 2165-2172	13
562	Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management. 2018 , 59, 311-320	29
561	Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies. 2018 , 11, 1-12	5
560	Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies. 2018 , 97, 1-15	26
559	Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors. 2018 , 59, 1554-1564	29
558	Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. 2018 , 32, 920-930	25
557	Reduced intensity is preferred over myeloablative conditioning allogeneic HCT in chronic lymphocytic leukemia whenever indicated: A systematic review/meta-analysis. 2018 , 11, 53-64	8
556	Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. 2018 , 391, 659-667	231

555	Acalabrutinib: First Global Approval. 2018 , 78, 139-145	34
554	What is the optimal management of older CLL patients?. 2018 , 31, 83-89	3
553	Novel agents for relapsed and refractory follicular lymphoma. 2018 , 31, 41-48	16
552	Novel therapies for relapsed/refractory mantle cell lymphoma. 2018 , 31, 105-113	9
551	Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). 2018 , 27, 31-42	45
550	Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors. 2018 , 182, 718-723	1
549	Chronic lymphocytic leukaemia: A guide for practice nurses. 2018 , 29, 256-259	
548	Mechanisms of Drug Resistance in Cancer Therapy. 2018 ,	
547	Relapsed CLL: sequencing, combinations, and novel agents. 2018 , 2018, 248-255	7
546	The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity. 2018 , 38, 17-62	53
545	Ibrutinib-related bleeding: pathogenesis, clinical implications and management. 2018 , 29, 481-487	15
544	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. <i>New England Journal of Medicine</i> , 2018 , 379, 2517-2528	59.2 455
543	Toward the potential cure of leukemias in the next decade. 2018 , 124, 4301-4313	20
542	The B cell receptor signaling pathway in mantle cell lymphoma. 2018 , 9, 25332-25341	27
541	Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation. 2018 , 9, 2027	7
540	Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies. 2018 , 78, 1653-1663	25
539	Identification of Distinct Unmutated Chronic Lymphocytic Leukemia Subsets in Mice Based on Their T Cell Dependency. 2018 , 9, 1996	6
538	Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation. 2018 , 97, 2269-2278	18

537	Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma. 2018 , 13, 543-554	23
536	Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors. 2018 , 28, 3307-3311	4
535	On the front line: first choice pharmacotherapeutics for chronic lymphocytic leukemia. 2018 , 19, 1675-1684	
534	The Chemoimmunotherapy Era in CLL is Over. 2018 , 18, S116-S119	
533	Genomikus k�piasz�n-elt�r�sek sz�ke kr�nikus limfoid leuk�miaban multiplex lig�ndig�g� szondaamplifik�ci�val. 2018 , 51, 31-40	
532	Pitfalls of Combining Novel Agents in Lymphoma. 2018 , 19, 35	0
531	Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. 2018 , 32, 2388-2398	17
530	Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. 2018 , 15, 510-527	73
529	A safety profile of medications used to treat Waldenstr�m's macroglobulinemia. 2018 , 17, 609-621	2
528	The future of chronic lymphocytic leukemia: potential directions from ASH 2017. 2018 , 11, 481-486	
527	Targeted Treatments for Hematological Cancers. 2018 , 259-312	
526	Targeting the B cell receptor pathway in non-Hodgkin lymphoma. 2018 , 27, 513-522	29
525	Acquired platelet antagonism: off-target antiplatelet effects of malignancy treatment with tyrosine kinase inhibitors. 2018 , 16, 1686-1699	20
524	Auranofin Enhances Ibrutinib's Anticancer Activity in EGFR-Mutant Lung Adenocarcinoma. 2018 , 17, 2156-2163	23
523	First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenstr�m Macroglobulinemia. 2018 , 32, 853-864	3
522	New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?. 2018 , 11, 749-756	6
521	Resistance of Targeted Therapies Excluding Antibodies for Lymphomas. 2018 ,	
520	Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3K�. 2018 , 26, 4537-4543	11

519	The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC). 2018 , 101, 604	26
518	Move along, nothing to see here: Btk inhibitors stop platelets sticking to plaques. 2018 , 16, 1461	1
517	Vigilance for ibrutinib-associated ventricular arrhythmias: rare but be aware. 2018 , 59, 2767-2768	1
516	Small Molecules in Hematology. 2018 ,	4
515	Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor. 2018 , 212, 285-294	11
514	Bruton's Tyrosine Kinase, a Component of B Cell Signaling Pathways, Has Multiple Roles in the Pathogenesis of Lupus. 2017 , 8, 1986	24
513	NF- κ B Activation in Lymphoid Malignancies: Genetics, Signaling, and Targeted Therapy. 2018 , 6,	22
512	Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines. 2018 , 10,	16
511	Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement. 2018 , 23, 919-929	13
510	Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. 2018 , 132, 1039-1049	32
509	High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. 2018 , 132, 892-902	64
508	Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI. 2018 , 103, 2097-2108	41
507	Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors. 2018 , 351, e1700369	18
506	Use of acalabrutinib in patients with mantle cell lymphoma. 2018 , 11, 495-502	6
505	First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. 2018 , 9, 13023-13035	45
504	The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. 2018 , 8, 1300-1315	73
503	Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes. 2018 , 183, 212-224	11
502	A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia. 2018 , 14, 2229-2237	29

501	PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. 2018 , 28, 779-781	148
500	Severe arthritic syndrome due to ibrutinib use for chronic lymphocytic leukemia. 2019 , 25, 1003-1005	4
499	Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment. 2019 , 291, 190-213	40
498	Neue Therapiemöglichkeiten für Patienten mit CLL. 2019 , 22, 18-24	
497	Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. 2019 , 62, 7643-7655	47
496	Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. 2019 , 134, 851-859	151
495	Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase. 2019 , 62, 7923-7940	108
494	Frontline therapies for untreated chronic lymphoid leukemia. 2019 , 8, 15	10
493	Neue Therapiemöglichkeiten für Patienten mit CLL. 2019 , 22, 47-55	
492	Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia. 2019 , 17, 883-893	8
491	How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options. 2019 , 21, 74	4
490	Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate Lu-NNV003. 2019 , 46, 2311-2321	8
489	Advances in drug-based therapies in chronic lymphocytic leukemia and future prospects. 2019 , 2, e51	
488	Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia. 2019 , 185-190	1
487	Single and combined BTK and PI3K inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas. 2019 , 187, 595-601	8
486	Acid-Catalyzed Intramolecular Imination / Nucleophilic Trapping of 4-Aminobutanal Derivatives: One-Pot Access to 2-(Pyrazolyl)pyrrolidines. 2019 , 2019, 5709-5719	6
485	Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. 2019 , 94, 1266-1287	198
484	Chronic lymphocytic leukaemia: from genetics to treatment. 2019 , 16, 684-701	85

483	Contemporary management of nodal and primary splenic marginal zone lymphoma. 2019 , 12, 1011-1022	2
482	Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation. 2019 , 26, 1486-1500	55
481	Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia. 2019 , 10, 291-300	11
480	Convenient synthesis of 2-(het)arylpyrrolidines via stable 1-pyrrolinium salts. 2019 , 75, 130681	4
479	CAR-T "the living drugs", immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy. 2019 , 12, 113	42
478	MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications. 2019 , 104, 2337-2348	22
477	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. 2019 , 94, 1353-1363	152
476	Synthesis of Novel 2-(Het)arylpyrrolidine Derivatives and Evaluation of Their Anticancer and Anti-Biofilm Activity. 2019 , 24,	10
475	Acid-Catalyzed Cascade Reaction of 4-Aminobutanal Derivatives with (Hetero)aromatic Nucleophiles: A Versatile One-Pot Access to 2-(Hetero)arylpyrrolidines.. 2019 , 4, 9322-9330	8
474	Resistance to Targeted Therapies in Lymphomas. 2019 ,	
473	Novel BTK inhibitor acalabrutinib (ACP-196) tightly binds to site I of the human serum albumin as observed by spectroscopic and computational studies. 2019 , 127, 536-543	15
472	Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib. 2019 , 119, 397-406	21
471	The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents. 2019 , 104, e307-e309	11
470	Novel pathway inhibitors for the treatment of chronic lymphocytic leukaemia. 2019 , 6, e65-e66	1
469	New roles for B cell receptor associated kinases: when the B cell is not the target. 2019 , 33, 576-587	14
468	Development of BTK inhibitors for the treatment of B-cell malignancies. 2019 , 42, 171-181	28
467	The STELLAR trial protocol: a prospective multicentre trial for Richter's syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly diagnosed RS and a single-arm platform study for evaluation of novel agents in relapsed disease. 2019 , 19, 471	11
466	Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia. 2019 , 14, 292-301	9

465	The Proteome-Wide Potential for Reversible Covalency at Cysteine. 2019 , 58, 11385-11389	19
464	Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas. 2019 , 9, 443	20
463	The Proteome-Wide Potential for Reversible Covalency at Cysteine. 2019 , 131, 11507	
462	Chronic Lymphocytic Leukemia: Who, How, and Where?. 2019 , 3-17	2
461	Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach. 2019 , 8, 489-499	19
460	Prognostic Markers. 2019 , 53-65	
459	Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screens. 2019 , 27, 2905-2913	7
458	Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs?. 2019 , 119, 1212-1221	21
457	Treating Older Patients with Chronic Lymphocytic Leukemia: A Personalized Approach. 2019 , 36, 841-851	
456	Autoimmune Cytopenia in Chronic Lymphocytic Leukemia. 2019 , 123-136	
455	Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. 2019 , 26, e233-e240	48
454	Pharmacokinetic-pharmacodynamic models that incorporate drug-target binding kinetics. 2019 , 50, 120-127	12
453	Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes. 2019 , 12, 996-1006	30
452	Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factors. 2019 , 8, 2233-2240	7
451	Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. 2019 , 7, 9	16
450	Chronic Lymphocytic Leukemia. 2019 ,	
449	Targeting BTK in CLL: Beyond Ibrutinib. 2019 , 14, 197-205	65
448	Novel agents may positively impact chemotherapy and transplantation in subsets of diffuse large B-cell lymphoma. 2019 , 12, 407-418	3

447	Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis. 2019 , 169, 121-143	14
446	Modulation of immune checkpoint molecule expression in mantle cell lymphoma. 2019 , 60, 2498-2507	10
445	Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions. 2019 , 104, 2292-2299	25
444	Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium. 2019 , 16, 1374-1382	32
443	Acalabrutinib for mantle cell lymphoma. 2019 , 133, 2570-2574	13
442	Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies. 2019 , 14, 125-138	24
441	Chemotherapy and Beyond: Infections in the Era of Old and New Treatments for Hematologic Malignancies. 2019 , 33, 289-309	16
440	Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia. 2019 , 12, 15	25
439	Covalent Inhibition in Drug Discovery. 2019 , 14, 889-906	101
438	Impact of dosing frequency (once daily or twice daily) on patient adherence to oral targeted therapies for hematologic malignancies: a retrospective cohort study among managed care enrollees. 2019 , 25, 1897-1906	4
437	Bruton's Tyrosine Kinase (BTK) Inhibitors as Sensitizing Agents for Cancer Chemotherapy. 2019 , 109-124	1
436	Staging and general management. 2019 ,	
435	New Protein Markers of Chronic Lymphocytic and Acute Lymphocytic Leukemia. 2019 ,	
434	Articles Title ch_5. 2019 ,	
433	Sequential and combination treatments with novel agents in chronic lymphocytic leukemia. 2019 , 104, 2144-2154	19
432	Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. 2019 , 3, 1553-1562	101
431	Hypertension and incident cardiovascular events following ibrutinib initiation. 2019 , 134, 1919-1928	79
430	Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcRIIA): a new option in HIT?. 2019 , 3, 4021-4033	20

429	Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin β ₃ in mice and humans. 2019 , 3, 4298-4311	27
428	New drugs for the management of relapsed or refractory diffuse large B-cell lymphoma. 2019 , 3, 10-10	4
427	Targeted Therapy in Chronic Lymphocytic Leukemia. 2019 , 25, 378-385	14
426	Cancer biomarkers for targeted therapy. 2019 , 7, 25	38
425	Emerging treatment options for patients with p53-pathway-deficient CLL. 2019 , 10, 2040620719891356	12
424	From Biology to Therapy: The CLL Success Story. 2019 , 3, e175	29
423	Bruton Tyrosine Kinase Inhibitors: Present and Future. 2019 , 25, 386-393	34
422	Resistance Mechanisms to Targeted Agents in Chronic Lymphocytic Leukemia. 2019 , 25, 428-435	8
421	Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine?. 2019 , 3, e287	19
420	Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3K. 2019 , 164, 304-316	10
419	Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies. 2019 , 58, 659-672	7
418	The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia. 2019 , 33, 287-298	22
417	Acalabrutinib and its use in treatment of chronic lymphocytic leukemia. 2019 , 15, 579-589	18
416	Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors. 2019 , 29, 225-229	8
415	Novel Bruton tyrosine kinase inhibitor acalabrutinib quantification by validated LC-MS/MS method: An application to pharmacokinetic study in Sprague Dawley rats. 2019 , 164, 509-513	8
414	Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans. 2019 , 47, 145-154	23
413	Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)?. 2019 , 133, 121-129	13
412	Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia. 2019 , 144, 2762-2773	8

411	Lysine-Targeted Inhibitors and Chemoproteomic Probes. 2019 , 88, 365-381	42
410	Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study. 2019 , 60, 1972-1977	19
409	Acalabrutinib for adults with mantle cell lymphoma. 2019 , 12, 179-187	9
408	How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. 2019 , 133, 1298-1307	73
407	Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL. 2019 , 33, 1148-1160	11
406	Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017. 2019 , 18, 470-481	11
405	Role of Clinical Pharmacodynamics Studies in the Era of Precision Medicines Against Cancer. 2019 , 1-18	1
404	Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. 2019 , 184, 558-569	51
403	Bruton tyrosine kinase degradation as a therapeutic strategy for cancer. 2019 , 133, 952-961	73
402	TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib. 2019 , 79, 360-371	23
401	Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme. 2019 , 184, 667-671	14
400	The Exploration of Chirality for Improved Druggability within the Human Kinome. 2020 , 63, 441-469	16
399	Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. 2020 , 34, 787-798	185
398	Electrophysiology Translational Considerations in Cardio-Oncology: QT and Beyond. 2020 , 13, 390-401	7
397	Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections. 2020 , 40, 100635	20
396	Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo. 2020 , 151, 104512	6
395	Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy. 2020 , 95, E16-E18	2
394	Bruton tyrosine-kinase inhibitor on the rise: acalabrutinib in Waldenström macroglobulinemia. 2020 , 7, e85-e86	1

393	Advances in relapsed/refractory follicular lymphoma therapeutics. 2020 , 3, e74	1
392	An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. 2020 , 21, 29-38	3
391	Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. 2020 , 7, e112-e121	65
390	Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties. 2020 , 30, 126877	42
389	Discovery and Evaluation of Pyrazolo[3,4-]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor. 2020 , 11, 1863-1868	4
388	Minimizing and managing treatment-associated complications in patients with chronic lymphocytic leukemia. 2020 , 13, 39-53	5
387	Follicular Lymphoma. 2020 ,	
386	Chronic Lymphocytic Leukemia. 2020 , 1850-1871.e5	1
385	Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib. 2020 , 372, 331-338	10
384	Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL. 2019 , 21,	16
383	Overexpression of SH2-Containing Inositol Phosphatase Contributes to Chronic Lymphocytic Leukemia Survival. 2020 , 204, 360-374	5
382	Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib. 2020 , 43, 107-120	28
381	Development and Validation of Novel HPLC Bioanalytical Analysis Method for Acalabrutinib: An Anticancer Drug in Human Plasma. 2020 , 32, 2606-2610	0
380	A fit for purpose synthesis of Bruton's tyrosine kinase inhibitor GDC-0852. 2020 , 61, 152447	4
379	Bicyclobutane Carboxylic Amide as a Cysteine-Directed Strained Electrophile for Selective Targeting of Proteins. 2020 , 142, 18522-18531	22
378	Effects of novel Btk and Syk inhibitors on platelet functions alone and in combination in vitro and in vivo. 2020 , 18, 3336-3351	4
377	Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma. 2020 , 4, 4802-4811	12
376	Risk of infection associated with new therapies for lymphoproliferative syndromes. 2020 , 154, 101-107	4

375	Hydrogen Peroxide Inducible JAK3 Covalent Inhibitor: Prodrug for the Treatment of RA with Enhanced Safety Profile. 2020 , 11, 2182-2189	3
374	Next-Generation Bruton Tyrosine Kinase Inhibitors. 2020 , 38, 2937-2940	1
373	Exploring the Mechanism of Covalent Inhibition: Simulating the Binding Free Energy of Ketoamide Inhibitors of the Main Protease of SARS-CoV-2. 2020 , 59, 4601-4608	23
372	Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs. 2021 , 144, 365-379	5
371	Repurposing Anti-Cancer Drugs for COVID-19 Treatment. 2020 , 14, 5045-5058	14
370	Chemotherapy-free frontline therapy for CLL: is it worth it?. 2020 , 2020, 24-32	5
369	Managing toxicities of Bruton tyrosine kinase inhibitors. 2020 , 2020, 336-345	28
368	Role of Clinical Pharmacodynamics Studies in the Era of Precision Medicines Against Cancer. 2020 , 343-360	
367	Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma. 2020 , 34, 903-921	11
366	Treatment of Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2020 , 383, 460-473	59.2 75
365	Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date. 2020 , 13, 6573-6581	5
364	The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19. 2020 , 11, 1991	56
363	A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. 2020 , 126, 4485-4497	12
362	[Current diagnosis and treatment of chronic lymphocytic leukaemia]. 2020 , 145, 1139-1144	0
361	Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase. 2020 , 142, 2443-2455	43
360	Inhibition of Bruton tyrosine kinase by acalabrutinib dampens lipopolysaccharide/galactosamine-induced hepatic damage. 2020 , 131, 110736	4
359	Tailor-made amino acid-derived pharmaceuticals approved by the FDA in 2019. 2020 , 52, 1227-1261	16
358	An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia. 2020 , 13, 1039-1046	1

357	BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia. 2020 , 11, 2158	19
356	Simultaneous measurement of acalabrutinib, ibrutinib, and their metabolites in beagle dog plasma by UPLC-MS/MS and its application to a pharmacokinetic study. 2020 , 191, 113613	2
355	Discovery of a highly potent and selective Bruton's tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma. 2020 , 5, 200	1
354	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. 2020 , 4, 3977-3989	30
353	Structural and biophysical insights into the mode of covalent binding of rationally designed potent BMX inhibitors. 2020 , 1, 251-262	2
352	Importance of Crosstalk Between Chronic Lymphocytic Leukemia Cells and the Stromal Microenvironment: Direct Contact, Soluble Factors, and Extracellular Vesicles. 2020 , 10, 1422	11
351	Cardio-Oncology: A Win-Win Situation: How Solving the Mystery of an Ibrutinib Off-Target Effect Reveals New Insights Into Atrial Fibrillation Mechanisms. 2020 , 142, 2456-2458	7
350	Zanubrutinib for the treatment of Waldenström Macroglobulinemia. 2020 , 13, 1303-1310	0
349	Infectious Complications of Tyrosine Kinase Inhibitors in Hematological Malignancies. 2020 , 34, 245-256	6
348	UGT2B17 modifies drug response in chronic lymphocytic leukaemia. 2020 , 123, 240-251	5
347	Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. 2020 , 26, 2810-2818	32
346	Low-dose Btk inhibitors selectively block platelet activation by CLEC-2. 2021 , 106, 208-219	20
345	Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib. 2020 , 26, 2800-2809	8
344	Btk SH2-kinase interface is critical for allosteric kinase activation and its targeting inhibits B-cell neoplasms. 2020 , 11, 2319	12
343	Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. 2020 , 13, 48	41
342	Nonclinical Safety Assessment of Zanubrutinib: A Novel Irreversible BTK Inhibitor. 2020 , 39, 232-240	5
341	Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies. 2020 , 12,	15
340	Investigational treatments for chronic lymphocytic leukemia: a focus on phase 1 and 2 clinical trials. 2020 , 29, 709-722	4

339	Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold. 2020 , 199, 112339	8
338	ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. 2020 , 38, 2849-2861	131
337	Selinexor for advanced hematologic malignancies. 2020 , 61, 2335-2350	7
336	Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects. 2020 , 4, 2439-2450	9
335	Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. 2020 , 5,	217
334	TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors. 2020 , 29, 869-880	6
333	Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. 2020 , 33,	32
332	Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape. 2020 , 21, 24	22
331	Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived. 2020 , 22, 36	14
330	Advances in targeted therapy for malignant lymphoma. 2020 , 5, 15	26
329	Ibrutinib in primary central nervous system diffuse large B-cell lymphoma. 2020 , 9, CNS51	5
328	Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction. 2020 , 25, 112-117	6
327	Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia. 2020 , 10, 394-405	38
326	Advances in covalent kinase inhibitors. 2020 , 49, 2617-2687	69
325	Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents. 2020 , 10, 894	22
324	Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors. 2020 , 21, 799-812	21
323	Prognostic and Predictive Molecular Biomarkers in Chronic Lymphocytic Leukemia. 2020 , 22, 1114-1125	8
322	B cell signalling pathways-New targets for precision medicine in chronic lymphocytic leukaemia. 2020 , 92, e12931	4

321	Fine-tuning front-line therapy in chronic lymphocytic leukemia. 2020 , 13, 259-265	0
320	The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia. 2020 , 20, 663-674	4
319	Occupy BTK: the key to controlling CLL. 2020 , 136, 4-6	8
318	The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity. 2020 , 189, e9-e13	1
317	Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia. 2020 , 9,	7
316	New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia. 2020 , 69, 867-877	3
315	Prevention of hepatitis B virus reactivation in patients with hematological malignancies and resolved hepatitis B virus infection: a systematic review and meta-analysis. 2020 , 21, 160-169	0
314	Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition. 2020 , 1864, 129531	39
313	Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL. 2020 , 11, 577	32
312	Using Crystal Structures of Drug-Metabolizing Enzymes in Mechanism-Based Modeling for Drug Design. 2020 , 567-585	
311	Risk of infection associated with new therapies for lymphoproliferative syndromes. 2020 , 154, 101-107	
310	Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib. 2020 , 25, 25-35	10
309	Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. 2020 , 135, 1204-1213	81
308	Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?. 2020 , 111, 642-656	1
307	CAR-T treatment for hematological malignancies. 2020 , 68, 956-964	9
306	Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors. 2020 , 4, 1458-1463	16
305	Acalabrutinib for the initial treatment of chronic lymphocytic leukaemia. 2020 , 395, 1234-1236	0
304	The effect of ibrutinib on neutrophil and T cell functions. 2020 , 61, 2409-2418	10

303	BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL. 2020 , 11, 2040620720912990	5
302	Current Perspectives on Therapy for Chronic Lymphocytic Leukemia. 2020 , 40, 1-10	10
301	Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data. 2020 , 12, 2079-2085	20
300	Treating Leukemia in the Time of COVID-19. 2021 , 144, 132-145	37
299	Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers. 2021 , 87, 1824-1838	2
298	A Proteomic Approach to Understand the Clinical Significance of Acute Myeloid Leukemia-Derived Extracellular Vesicles Reflecting Essential Characteristics of Leukemia. 2020 , 20, 100017	5
297	Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies. 2021 , 193, 15-25	15
296	Investigational drugs for the treatment of diffuse large B-cell lymphoma. 2021 , 30, 25-38	7
295	Novel antiplatelet strategies targeting GPVI, CLEC-2 and tyrosine kinases. 2021 , 32, 29-41	5
294	Acalabrutinib-related second primary malignancies and nonmelanoma skin cancers in patients with chronic lymphocytic leukaemia (CLL): A systematic review and meta-analysis of randomised controlled trials (RCTs). 2021 , 2, 115-120	
293	Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances. 2021 , 35, 312-332	52
292	Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML. 2021 , 106, 104385	5
291	Current and Emerging Treatments for Waldenström Macroglobulinemia. 2021 , 144, 146-157	4
290	High-Risk Mantle Cell Lymphoma in the Era of Novel Agents. 2021 , 16, 8-18	1
289	Der Stand der Therapie bei der refraktären/rezidivierenden chronischen lymphatischen Leukämie: Neuartige Wirkstoffe im Fokus. 2021 , 8, 59-69	
288	Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. 2021 , 62, 1066-1076	2
287	Current and novel BTK inhibitors in Waldenström's macroglobulinemia. 2021 , 12, 2040620721989586	4
286	Treatment of Chronic Lymphocytic Leukemia. 2021 , 195-206	

285	Recent advances in activity-based probes (ABPs) and affinity-based probes (ABPs) for profiling of enzymes. 2021 , 12, 8288-8310	18
284	Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pandemic. 2021 , 144, 508-518	8
283	Covalent drugs in development for immune-mediated diseases. 2021 ,	
282	Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. 2021 , 14, 17	4
281	Single-Cell RNA-Seq Reveals LGALS1 and LAG3 as Novel Drivers of Ibrutinib Resistance in Chronic Lymphocytic Leukemia.	
280	EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia. 2021 , 26, 242-249	7
279	BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib. 2021 , 35, 1317-1329	9
278	Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease. 2021 , 206, 1454-1468	20
277	Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance. 2021 , 13,	9
276	Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. 2021 , 106, 2364-2373	21
275	Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease. 2021 , 13,	16
274	Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions. 2021 , 10,	2
273	Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. 2021 , 9, 630942	37
272	Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells. 2021 , 81, 669-684	0
271	Click Nucleophilic Conjugate Additions to Activated Alkynes: Exploring Thiol-yne, Amino-yne, and Hydroxyl-yne Reactions from (Bio)Organic to Polymer Chemistry. 2021 , 121, 6744-6776	23
270	Targeted In Vivo Delivery of NF-B Decoy Inhibitor Augments Sensitivity of B Cell Lymphoma to Therapy. 2021 , 29, 1214-1225	1
269	A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib. 2021 , 62, 2018-2021	1
268	Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. 2021 , 14, 40	18

267	Current and future treatment strategies in chronic lymphocytic leukemia. 2021 , 14, 69	2
266	From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct. 2021 , 13,	1
265	Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies. 2021 , 62, 2392-2399	0
264	Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. 2021 , 35, 3201-3211	4
263	Discovery of a Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase with Oral Anti-Inflammatory Activity. 2021 , 12, 782-790	1
262	Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment. 2021 , 70, 2439-2451	9
261	The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review. 2021 , 1	7
260	Current Treatment Options in CLL. 2021 , 13,	4
259	The intersection of COVID-19 and cancer: signaling pathways and treatment implications. 2021 , 20, 76	5
258	Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies. 2021 , 11, 668162	5
257	Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy. 2021 , 16, 325-335	0
256	Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study. 2021 , 112, 2405-2415	1
255	Targeting BTK Signaling in the Microenvironment of Solid Tumors as a Feasible Cancer Therapy Option. 2021 , 13,	6
254	Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma. 2021 , 21, 732	0
253	Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK. 2021 , 9, 655489	3
252	New drugs and pharmacological interactions in real life. 2021 , 39 Suppl 1, 78-82	
251	p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors. 2021 , 9, 690365	4
250	Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. 2021 , 128, 1973-1987	1

249	Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19. 2021 , 22,	7
248	To start and stop or just keep going?. 2021 , 138, 819-820	
247	A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel). 2021 , 194, 69-77	4
246	Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy. 2021 , 138, 836-846	6
245	Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma. 2021 , 21, 158-170	2
244	Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors. 2021 , 40, 116163	3
243	Targeting Bruton's Tyrosine Kinase in Inflammatory and Autoimmune Pathologies. 2021 , 9, 668131	4
242	ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models. 2021 , 137, 3365-3377	16
241	Acalabrutinib in treatment-naive chronic lymphocytic leukemia. 2021 , 137, 3327-3338	18
240	A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions. 2021 , 12, 681984	4
239	Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma. 2021 , 62, 2612-2624	4
238	Resistance Mutations to BTK Inhibitors Originate From the NF- κ B but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway. 2021 , 12, 689472	6
237	Targeting Bruton's Tyrosine Kinase in CLL. 2021 , 12, 687458	11
236	Targeting Protein Kinases Degradation by PROTACs. 2021 , 9, 679120	10
235	Synergistic efficacy of the dual PI3K- η inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models. 2021 , 137, 3378-3389	5
234	Autoimmune Cytopenia in CLL: Prognosis and Management in the Era of Targeted Therapies. 2021 , 27, 286-296	0
233	Acalabrutinib for treatment of diffuse large B-cell lymphoma: results from a phase Ib study. 2021 , 106, 2774-2778	3
232	Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. 2021 , 39, 3441-3452	65

231	Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia. 2021 , 17, 1023-1030	0
230	Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies. 2021 , 138, 1099-1109	2
229	Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia. 2021 , 27, 306-313	0
228	The future of antibody therapy in chronic lymphocytic leukemia. 2021 , 26, 323-336	0
227	A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies. 2021 , 62, 2625-2636	0
226	Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors. 2021 , 12, 694853	9
225	Bruton's tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma. 2021 , 10, 56	1
224	A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia. 2021 , 27, 5492-5501	6
223	Integrating New Therapies for Chronic Lymphocytic Leukemia. 2021 , 27, 275-285	1
222	Comparison of the drug-drug interactions potential of ibrutinib and acalabrutinib via inhibition of UDP-glucuronosyltransferase. 2021 , 424, 115595	0
221	Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors. 2021 , 35, 793-806	
220	Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL. 2021 , 5, 3134-3146	0
219	Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation. 2021 , 23, 113	9
218	A mechanism for localized dynamics-driven activation in Bruton's tyrosine kinase. 2021 , 8, 210066	1
217	Non-Covalent BTK Inhibitors-The New BTKids on the Block for B-Cell Malignancies. 2021 , 11,	8
216	Genomics of Resistance to Targeted Therapies. 2021 , 35, 715-724	
215	Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function.	1
214	Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets - Beyond B Lymphocytes. 2021 , 9, 727531	5

213	Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro. 2021 , 345, 109559	1
212	Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice. 2021 , 51, 2251-2265	2
211	First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?. 2021 , 35, 725-738	1
210	Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib. 2021 , 35, 761-773	2
209	Acalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence. 2021 , 23, 332-338	
208	Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. 2021 , 5, 3528-3539	6
207	Discovery of Covalent Bruton's Tyrosine Kinase Inhibitors with Decreased CYP2C8 Inhibitory Activity. 2021 ,	1
206	Subcutaneous panniculitis-like T cell lymphoma arising in association with chronic lymphocytic leukaemia. 2021 , 14,	
205	Platelet GPVI (Glycoprotein VI) and Thrombotic Complications in the Venous System. 2021 , 41, 2681-2692	2
204	Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK. 2021 , 13, 21102-21121	0
203	Effects of the Btk-Inhibitors Remibrutinib (LOU064) and Rilzabrutinib (PRN1008) With Varying Btk Selectivity Over Tec on Platelet Aggregation and Bleeding Time. 2021 , 8, 749022	1
202	The role of Bruton's tyrosine kinase in the immune system and disease. 2021 , 164, 722-736	10
201	Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib. 2021 , 14, 1329-1344	4
200	Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. 2021 ,	5
199	Case Presentation Relapse After Frontline BTKi Therapy in Patients with CLL: Options and Consideration. 2021 , 21, S40-S42	
198	Exposure-response analysis of acalabrutinib and its active metabolite, ACP-5862, in patients with B-cell malignancies. 2021 ,	1
197	Rapid improvement in symptoms and physical function following ibrutinib initiation in chronic lymphocytic leukemia and the associated changes in plasma cytokines. 2021 , 109, 106628	0
196	Recent progress in covalent warheads for in vivo targeting of endogenous proteins. 2021 , 47, 116386	4

195	Structure-activity relationship investigation for imidazopyrazole-3-carboxamide derivatives as novel selective inhibitors of Bruton's tyrosine kinase. 2021 , 225, 113724	5
194	Incorporating molecular biomarkers into the continuum of care in chronic lymphocytic leukemia. 2021 , 62, 1289-1301	0
193	The role of acalabrutinib in adults with chronic lymphocytic leukemia. 2021 , 12, 2040620721990553	3
192	The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia. 2021 , 12, 2040620721989588	3
191	Targeting Intraplatelet Signaling Pathways as Potential Antithrombotic Strategy. 2017 , 1341-1357	1
190	Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib drug response in chronic lymphocytic leukemia.	2
189	Resolution of lung adenocarcinoma after discontinuation of ibrutinib. 2016 , 2016,	0
188	Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis. 2020 , 130, 4759-4770	23
187	Ibrutinib treatment improves T cell number and function in CLL patients. 2017 , 127, 3052-3064	197
186	Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib. 2020 , 136, 93-105	34
185	BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. 2020 , 135, 2266-2270	35
184	Relapsed disease and aspects of undetectable MRD and treatment discontinuation. 2019 , 2019, 482-489	1
183	Treatment of relapsed chronic lymphocytic leukemia after venetoclax. 2020 , 2020, 18-23	3
182	Fragment-Based Discovery of Irreversible Covalent Inhibitors of Cysteine Proteases Using Chlorofluoroacetamide Library. 2020 , 68, 1074-1081	3
181	Recent therapeutic advances in chronic lymphocytic leukemia. 2017 , 6, 1924	12
180	Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside. 2017 , 8, 7201-7207	23
179	Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones. 2017 , 8, 35508-35522	40
178	Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling. 2017 , 8, 71981-71995	14

177	A novel high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia. 2018 , 9, 26019-26031	5
176	Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. 2019 , 10, 3827-3830	2
175	Promises and pitfalls of targeted agents in chronic lymphocytic leukemia.. 2020 , 3, 415-444	2
174	The Treatment of Chronic Lymphatic Leukemia. 2019 , 116, 41-46	7
173	Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia. 2020 , 27, e645-e655	2
172	Recent advances in chronic lymphocytic leukemia therapy. 2020 , 55, S72-S82	3
171	Synthesis and Theoretical Study of Novel Imidazo[4,5-b]pyrazine-Conjugated Benzamides as Potential Anticancer Agents. 2021 , 57, 1487-1494	
170	Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease. 2021 , 81, 1605-1626	5
169	Precision diagnostics in lymphomas - Recent developments and future directions. 2021 ,	0
168	Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis. 2021 ,	11
167	Driving Out Chronic Lymphocytic Leukemia With CAR T Cells. 2021 , 28, 5-5	0
166	Quantification and Stability Indicating UPLC Method Development and Validation of Acalabrutinib in Bulk and Pharmaceutical Dosage Form. 2021 , 11,	
165	Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. 2021 , 96, 1679-1705	19
164	Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapy. 2022 , 49, 61-81	1
163	Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively. 2021 , 40, 321	3
162	The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma. 2021 , 39, 605-615	1
161	The cure of leukemia through the optimist's prism. 2021 , 128, 240	2
160	Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia. 2021 , 12, 738915	7

- 159 Discovery of 1-Amino-1-imidazole-5-carboxamide Derivatives as Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitors. **2021**, 64, 16242-16270 2
- 158 Encyclopedia of Signaling Molecules. **2016**, 1-10
- 157 New Treatment Paradigms Defined for Chronic Lymphocytic Leukemia. **2017**, 8, 273-278
- 156 Encyclopedia of Signaling Molecules. **2018**, 587-595
- 155 Tyrosine Kinases, microRNAs, Epigenetics: New Insights in the Mechanisms of Leukemogenesis. **2018**, 11-25
- 154 Clinical Evaluation and Management of Chronic Lymphocytic Leukemia. **2019**, 401-409
- 153 Kinase Inhibitors in Large Cell Lymphoma. **2019**, 297-305
- 152 Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit. **2019**, 1-27
- 151 Resistance to Bruton's Tyrosine Kinase Signaling Pathway Targeted Therapies. **2019**, 111-153 1
- 150 Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia. **2019**, 107-119 1
- 149 Initial Therapy of Chronic Lymphocytic Leukemia. **2019**, 79-96 2
- 148 Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit. **2020**, 201-227
- 147 Chronic Lymphocytic Leukemia with Alterations in TP53. **2020**, 47-67
- 146 Neurological Complications of Targeted Therapies. **2020**, 341-363
- 145 Molecular Targeting in Follicular Lymphoma. **2020**, 207-218
- 144 Chronic lymphocytic leukaemia. **2020**, 5302-5310
- 143 HDAC1 regulates the chromatin landscape to establish transcriptional dependencies in chronic lymphocytic leukemia. 0
- 142 Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management. **2021**, 0

141	The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View. 2021 , 13, 923-935	4
140	Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies. 2021 , 11, 737943	1
139	Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. 2021 ,	6
138	Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study. 2021 , 8, e912-e921	8
137	Chapter 8:PROTAC Targeting BTK for the Treatment of Ibrutinib-resistant B-cell Malignancies. 2020 , 147-166	
136	Novel Therapeutics in the Management of Waldenström Macroglobulinemia. 2020 , 15-26	
135	Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures. 2021 , 12, 662223	4
134	Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice. 2021 , 11, 720704	8
133	Applications of Artificial Intelligence in Drug Design: Opportunities and Challenges. 2022 , 2390, 1-59	1
132	Risk of Bleeding Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 2020 , 11, 580622	3
131	New Pharmacotherapies in Chronic Lymphocytic Leukemia. 2017 , 42, 106-115	1
130	PI3K expression predicts overall survival in lung adenocarcinoma. 2018 , 11, 4889-4898	1
129	[Application of ibrutinib in primary central nervous system lymphoma]. 2020 , 41, 348-350	
128	The CLL12 trial: Ibrutinib versus placebo in treatment-naïve, early stage chronic lymphocytic leukemia. 2021 ,	5
127	Bruton's Tyrosine Kinase Inhibitors Impair Fc γ RIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.. 2021 , 12, 766272	2
126	Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past is Prologue" (Shakespeare). 2021 ,	2
125	ELEVATE-RR [First head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia. 2021 , 23, 404-406	
124	Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib. 2021 , 229, 114009	7

123	Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features.. 2021 , 11, 780085	1
122	Ex Vivo Validation of Six FDA-Approved Non-Receptor Tyrosine Kinase Inhibitors (NRTKIs) as Antivirals to Pandemic and Seasonal Influenza A Viruses.	0
121	Towards precision medicine in lymphoid malignancies. 2021 ,	1
120	Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia.. 2022 ,	0
119	CLL update 2022: A continuing evolution in care.. 2022 , 100930	1
118	Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies.. 2022 , 17, 39	
117	The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions.. 2022 , 14,	11
116	Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.. 2022 ,	1
115	Acalabrutinib in the management of chronic lymphocytic leukaemia. 2022 , 4, 72-80	
114	Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors.. 2021 ,	10
113	Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features.. 2021 , 17, 69	9
112	A novel LC-MS/MS method for simultaneous estimation of acalabrutinib and its active metabolite acalabrutinib M in human plasma and application to a human pharmacokinetic study.. 2022 , 12, 6631-6639	0
111	The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact.. 2022 ,	
110	Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.. 2022 , 1-9	
109	Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment.. 2021 ,	0
108	Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia.. 2022 , 6, e692	1
107	Real-world management of targeted therapies in chronic lymphocytic leukemia.. 2022 , 10781552221090869	1
106	Recent advances of nanodrug delivery system in the treatment of hematologic malignancies.. 2022 ,	0

105	New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia.. 2022 , 1	2
104	Discovery of Reversible Covalent Bruton’s Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib).. 2022 ,	2
103	Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion.. 2022 ,	10
102	Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies.. 2022 , 1	2
101	Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence.. 2022 , 11,	1
100	Novel Bruton’s Tyrosine Kinase (BTK) substrates for time-resolved luminescence assays.	
99	BTKi, venetoclax, obinutuzumab: what is the ideal combination?. 2022 , 15, 49-52	0
98	Tumor Microenvironment of Lymphomas and Plasma Cell Neoplasms: Broad Overview and Impact on Evaluation for Immune Based Therapies.. 2021 , 11, 719140	0
97	Upfront therapy: the case for continuous treatment. 2021 , 2021, 55-58	
96	Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies.. 2021 , 7,	3
95	Understanding CLL biology through mouse models of human genetics.. 2021 , 138, 2621-2631	1
94	Phase 1b dose-escalation study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies.. 2021 ,	3
93	FDA-Approved Drugs for Hematological Malignancies-The Last Decade Review.. 2021 , 14,	4
92	Pharmacoeconomic analysis of acalabrutinib in patients with chronic lymphocytic leukemia. 2021 , 23, 612-620	1
91	Infectious complications in patients with chronic lymphocytic leukemia treated with bruton’s tyrosine kinase inhibitors. 2021 , 21, 15-27	
90	Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib.. 2021 , 14, 5507-5519	0
89	Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia.. 2022 ,	0
88	Cardiotoxicity of BTK inhibitors: ibrutinib and beyond.. 2022 ,	2

- 87 The Ascension of Targeted Covalent Inhibitors.. **2022**, 3
- 86 Data_Sheet_1.PDF. **2018**,
- 85 Table_1.DOC. **2018**,
- 84 Table_2.DOC. **2018**,
- 83 Table_3.DOC. **2018**,
- 82 Table_4.DOC. **2018**,
- 81 Table_5.docx. **2018**,
- 80 Table_6.DOC. **2018**,
- 79 Table_7.DOC. **2018**,
- 78 Image_1.PDF. **2018**,
- 77 Image_2.JPEG. **2018**,
- 76 Image_3.JPEG. **2018**,
- 75 Image_4.JPEG. **2018**,
- 74 Image_5.JPEG. **2018**,
- 73 Data_Sheet_1.doc. **2020**,
- 72 Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapy.. **2022**, ○
- 71 Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib and acalabrutinib treated patients.. **2022**, ○
- 70 Phosphoproteomics Reveals the Role of Constitutive KAP1 Phosphorylation by B-Cell Receptor Signaling in Chronic Lymphocytic Leukemia.. **2022**,

- 69 [F]BTK-1: A Novel Positron Emission Tomography Tracer for Imaging Bruton's Tyrosine Kinase.. **2022**, 1 0
- 68 Cancers of the Blood. **2022**, 67-131
- 67 Discovery of pyrrolo[1,2-a]quinoxalin-4(5H)-one Derivatives as Novel Non-covalent Bruton's Tyrosine Kinase (BTK) inhibitors. **2022**, 105860
- 66 Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. **2022**, 12, 3
- 65 Novel Bruton's Tyrosine Kinase (BTK) Substrates for Time-Resolved Luminescence Assays.
- 64 Acute and chronic leukemias. **2023**, 403-411
- 63 Kinase-deficient BTK mutants confer ibrutinib resistance through activation of the kinase HCK. **2022**, 15, 0
- 62 Design, Synthesis, In Silico Studies and Inhibitory Activity towards Bcr-Abl, BTK and FLT3-ITD of New 2,6,9-Trisubstituted Purine Derivatives as Potential Agents for the Treatment of Leukaemia. **2022**, 14, 1294
- 61 Zanubrutinib for the Treatment of B-cell Malignancies. **2022**, 18, 44
- 60 The Dosing of Ibrutinib and Related Bruton's Tyrosine Kinase Inhibitors: Eliminating the Use of Brute Force.
- 59 Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation. **2022**, 15, 2
- 58 Integrin Signaling Shaping BTK-Inhibitor Resistance. **2022**, 11, 2235
- 57 Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance. Volume 12, 81-98 0
- 56 Practical management of chronic lymphocytic leukemia with acalabrutinib. 1-10
- 55 TP53 Abnormalities Are Underlying the Poor Outcome Associated with Chromothripsis in Chronic Lymphocytic Leukemia Patients with Complex Karyotype. **2022**, 14, 3715 1
- 54 Decreased cell proliferation and induced apoptosis in human B-chronic lymphocytic leukemia following miR-221 inhibition through modulation of p27 expression. **2022**, 23, 0
- 53 Next-generation Bruton's tyrosine kinase (BTK) inhibitors potentially targeting BTK C481S mutation- Recent developments and Perspectives.. **2022**, 22, 2
- 52 Determining drug dose in the era of targeted therapies: playing it (un)safe?. **2022**, 12,

51	Advances in covalent drug discovery.	9
50	Platelets and tyrosine kinase inhibitors: clinical features, mechanism of action and effects on physiology.	0
49	Beyond ibrutinib: novel BTK inhibitors for the treatment of chronic lymphocytic leukemia. Publish Ahead of Print,	2
48	Ventricular Arrhythmias and Sudden Death Events following Acalabrutinib initiation.	3
47	Immunotherapy for Bladder Cancer: Latest Advances and Ongoing Clinical Trials. 1-26	1
46	Nanotechnological application of peptide- and protein-based therapeutics. 2022 , 205-238	1
45	B cell receptor (BCR) endocytosis. 2022 ,	0
44	Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy. 13,	1
43	Exploring the Role of Chemical Reactions in the Selectivity of Tyrosine Kinase Inhibitors. 2022 , 144, 16638-16646	6
42	Orelabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients: Multi-center, Single-arm, Open-label, Phase 2 Study.	0
41	Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical. Volume 16, 3225-3239	0
40	MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. 00-00	0
39	Loss of BTK ameliorates the pathological cardiac fibrosis and dysfunction. 2022 , 112, 171-189	0
38	Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner. 2022 , 14, 1876	0
37	BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. 2022 , 15,	1
36	Structural characterization of novel hydrolytic and oxidative degradation products of acalabrutinib by LC-Q-TOF-MS, H/D exchange and NMR. 2022 , 221, 115077	0
35	Bruton Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis. 2022 , 11, 6139	1
34	NF- κ B Mutations in Germinal Center B-Cell Lymphomas: Relation to NF- κ B Function in Normal B Cells. 2022 , 10, 2450	0

33	Characterization of the SARS-CoV-2 co-receptor NRP1 expression profiles in healthy people and cancer patients: Implication for susceptibility to COVID-19 disease and potential therapeutic strategy. 13,	0
32	Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.	1
31	Chronic Lymphocytic Leukemia. 1-11	0
30	Identification and characterization of ACP-5862, the major circulating active metabolite of acalabrutinib: both are potent and selective covalent BTK inhibitors. JPET-AR-2022-001116	1
29	BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naïve mantle cell lymphoma.	1
28	Data mining and safety analysis of BTK inhibitors: A pharmacovigilance investigation based on the FAERS database. 13,	0
27	Evaluating orelabrutinib as a novel treatment option for relapsed/refractory chronic lymphocytic leukemia in China. 1-8	1
26	Immunotherapy combinations for chronic lymphocytic leukemia: advantages and disadvantages. 1-15	1
25	Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. 2022 ,	2
24	Design, synthesis and biological evaluation of novel pyrazolo-pyrimidin-amines as potent and selective BTK inhibitors. 2023 , 130, 106238	0
23	Adenosine 2A Receptor Activation Amplifies Ibrutinib Antiplatelet Effect; Implications in Chronic Lymphocytic Leukemia. 2022 , 14, 5750	0
22	Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential. 2022 , 14, 5787	0
21	Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders. 12,	0
20	Onconeurology 2022: An Update. 10.34067/KID.0001582022	0
19	Bireactive: Expanding the Scope of Reactivity Predictions to Propynamides. 2023 , 16, 116	0
18	Top Selling (2026) Small Molecule Orphan Drugs: A Journey into Their Chemistry. 2023 , 24, 930	0
17	Isolation and characterization of pseudo degradation products of acalabrutinib using ESI-HRMS/MS and NMR: Formation of possible geometrical isomers. 2023 , 225, 115214	0
16	Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study.	1

- 15 Recent revelations and future directions using single-cell technologies in chronic lymphocytic leukemia. **2023**, 13, ○
- 14 Genetic and Clinical Characteristics of Korean Chronic Lymphocytic Leukemia Patients with High Frequencies of MYD88 Mutations. **2023**, 24, 3177 ○
- 13 Synthesis and Preclinical Evaluation of a Novel Fluorine-18-Labeled Tracer for Positron Emission Tomography Imaging of Bruton's Tyrosine Kinase. **2023**, 6, 410-421 ○
- 12 Controlling Ibrutinib's Conformations about Its Heterobiaryl Axis to Increase BTK Selectivity. **2023**, 14, 305-311 ○
- 11 Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis. **2023**, 64, 712-716 ○
- 10 FDA-approved Abl/EGFR/PDGFR kinase inhibitors show potent efficacy against pandemic and seasonal influenza A virus infections of human lung explants. **2023**, 26, 106309 ○
- 9 Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials. **2023**, 28, 2400 ○
- 8 Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases. **2023**, 66, 4025-4044 ○
- 7 Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer. **2023**, 15, 1766 ○
- 6 Evaluation of bleeding events in patients receiving acalabrutinib therapy. ○
- 5 Acalabrutinib in chronic lymphocytic leukemia. **2023**, 24, 545-549 1
- 4 Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Monotherapy Compared with Combination Therapy for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Systematic Review and Meta-Analysis. **2023**, 15, 1996 ○
- 3 Time and personnel costs associated with adverse event (AE) management among patients with chronic lymphocytic leukemia (CLL). 1-8 ○
- 2 How We Manage Patients with Indolent B-Cell Malignancies on Bruton's Tyrosine Kinase Inhibitors: Practical Considerations for Nurses and Pharmacists. **2023**, 30, 4222-4245 ○
- 1 Targeted therapy. **2023**, 205-411 ○